Ancrod

DRUG2 trials

Sponsors

Heidelberg University, Nordmark Arzneimittel GmbH & Co. KG

Conditions

Acute StrokeBrain InfarctionCerebral IschemiaDeafnessEar DiseasesHearing DisordersHearing LossHearing Loss, Sensorineural

Phase 1

Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss

CompletedNCT01621256

Nordmark Arzneimittel GmbH & Co. KGDeafness, Ear Diseases, Hearing Disorders +2

Start: 2013-05-31End: 2018-10-30Updated: 2018-12-21

Phase 3

Intravenous Ancrod for the Treatment of Acute Ischemic Stroke Within 6 Hours After Onset of Symptoms

CompletedNCT00343174

Heidelberg UniversityAcute Stroke, Brain Infarction, Cerebral Ischemia

Updated: 2006-06-22

Related Papers

Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial.

2006-11-0179 citations